Australia: A highly attractive environment for drug development
Australia offers a highly favorable environment for drug research and development, with a mature infrastructure and experienced, capable local resources and expertise. Considering global geopolitical uncertainties, Australia presents a compelling option for sponsors to consider. This first article in a three-part series illustrates the Australian economy, demographics, healthcare investments and expenditures, and the growth of the pharmaceutical market and clinical trials. Ensuing articles will explore the landscape for clinical trials, including the therapeutic areas, the strength of patient centricity and innovation adoption, and the regulatory and reimbursement environment.
Interested in more? Check out part 2 and part 3.
Related Insights
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Article
Can Chinese Phase I data from the West accelerate China drug development?
Mar 17, 2021
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Article
Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?
Jun 30, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
India, the Generic Manufacturing Powerhouse, Biosimilar Next?
Jul 21, 2021
Article
Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
Aug 6, 2021
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Blog
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Report
Chapter 2: Beyond the Binary: Navigating Gender Diversity in Clinical Research
Jul 23, 2024
Related Insights
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Article
Can Chinese Phase I data from the West accelerate China drug development?
Mar 17, 2021
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Article
Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?
Jun 30, 2021
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Article
India, the Generic Manufacturing Powerhouse, Biosimilar Next?
Jul 21, 2021
Article
Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
Aug 6, 2021
Blog
Highlights from ISMPP Asia Pacific Meeting 2021
Sep 20, 2021
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Blog
CNS Summit Recap: The Future is Collaborative
Nov 22, 2021
Report
Chapter 2: Beyond the Binary: Navigating Gender Diversity in Clinical Research
Jul 23, 2024